Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Rome – page 56

2 209 clinical trials in Rome, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Rome at a glance
2 209
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 209 trials in Rome

Open in trial search

Post transplant lymphoproliferative disorder+1

Recruiting

Study of Tabelecleucel for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Transplant Treatment Failure

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Adenocarcinoma of colon

Recruiting

Study on Temozolomide and Irinotecan for Patients with Stage II/III Colorectal Cancer and Positive ctDNA After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Breast cancer

Recruiting

Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer stage III+3

Recruiting

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Epstein-Barr virus associated lymphoproliferative disorder

Recruiting

Study on Tabelecleucel for Patients with Epstein-Barr Virus-Associated Diseases

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Duchenne muscular dystrophy

Recruiting

Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Myotonic dystrophy

Recruiting

Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings SA

Clostridium difficile infection

Recruiting

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bacilli, Cluster Xvii, Strain Relative Clostridium_Aq Innocuum, Live
  • Sponsor:Vedanta Biosciences Inc.

Cardiac failure

Recruiting

Study on Colchicine and Thiamine for Patients with Heart Failure from Ischemic Heart Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Acute lymphocytic leukaemia+4

Recruiting

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ruxolitinib
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Rome

What the registry says about research in the country

01 Respiratory Diseases

Clinical studies focusing on Idiopathic Pulmonary Fibrosis and COPD, evaluating new therapeutic approaches for improving lung function and reducing disease progression.

  • Pulmonary function assessment
  • Disease exacerbation prevention
  • RSV prevention in high-risk populations

Advanced research includes novel antibody treatments and preventive measures for respiratory infections.

02 Oncology Research

Innovative trials targeting metastatic colorectal cancer, gastric cancer, and acute myeloid leukemia, exploring new treatment combinations and targeted therapies.

  • Targeted molecular therapies
  • Combination treatment approaches
  • Advanced stage cancer management

Studies focus on improving response rates and survival outcomes in various cancer types.

03 Neurological Conditions

Research into Parkinson's disease and acute ischemic stroke, investigating novel therapeutic approaches and neuroprotective strategies.

  • Early disease intervention
  • Stroke treatment optimization
  • Disease-modifying therapies

Studies aim to improve neurological outcomes and patient quality of life.

04 Immunological Disorders

Clinical trials examining Immune Thrombocytopenia and Hidradenitis Suppurativa, testing new therapeutic agents for immune-mediated conditions.

  • Immune system modulation
  • Novel biological therapies
  • Long-term disease management

Research focuses on improving treatment outcomes in challenging immune disorders.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.